Zoetis Inc Intrinsic Value Calculation – Zoetis Receives $13.5M Grant from Bill & Melinda Gates Foundation to Expand African Livestock Productivity and Health Advancement Initiative in 2023.
March 2, 2023
Trending News ☀️
Zoetis Inc Intrinsic Value Calculation – Zoetis ($NYSE:ZTS) is proud to announce that it has been awarded a $13.5M grant from the Bill & Melinda Gates Foundation to further expand its African Livestock Productivity and Health Advancement initiative. This initiative seeks to strengthen veterinary services and develop cutting-edge solutions that can be used to improve animal health and productivity across Sub-Saharan Africa. Through this grant, Zoetis plans to expand its current program to include aquaculture, in addition to cattle, poultry, and swine, across seven more countries in the Sub-Saharan region. The initiative targets challenges in the livestock industry, such as lack of access to quality medical care for animals, outdated veterinary infrastructure, and insufficient access to diagnostics technology.
Through this program, Zoetis aims to increase livestock health, improve productivity, and ultimately help advance economic growth in Sub-Saharan African countries. It is believed that with these advancements, rural farmers will be able to build more sustainable livelihoods by increasing their agricultural output. Zoetis is committed to helping rural farmers improve their animal health and overall quality of life. The funds will help Zoetis expand its program to reach even more people and help make a positive change in their lives.
Stock Price
This news was met with mostly positive sentiment, as evidenced by the stock’s performance that day. The stock opened at $166.0 and closed at $167.6, up by 0.3% from the prior closing price of $167.0. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Zoetis Inc. More…
| Total Revenues | Net Income | Net Margin |
| 8.08k | 2.11k | 27.3% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Zoetis Inc. More…
| Operations | Investing | Financing |
| 1.91k | -883 | -904 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Zoetis Inc. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 14.93k | 10.52k | 9.5 |
Key Ratios Snapshot
Some of the financial key ratios for Zoetis Inc are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 8.9% | 13.2% | 35.6% |
| FCF Margin | ROE | ROA |
| 16.4% | 39.7% | 12.0% |
Analysis – Zoetis Inc Intrinsic Value Calculation
At GoodWhale, we have conducted an extensive analysis of ZOETIS INC‘s fundamentals and have concluded that the company is undervalued. Our proprietary Valuation Line has estimated the intrinsic value of ZOETIS INC shares to be around $188.7. Currently, the stock is trading at $167.6, making it a fair price that is undervalued by 11.2%. As a result, we believe that there could be potential upside for investors who invest in the stock at its current price. More…
Peers
Zoetis Inc. is a global animal health company that develops, manufactures, and markets a wide range of veterinary products. The company’s products include vaccines, parasiticides, pharmaceuticals, diagnostics, and biologics. Zoetis Inc. has a broad portfolio of products that are used in the prevention, treatment, and control of disease in animals. The company’s competitors include BioGaia AB, Krka d.d., and Phibro Animal Health Corp.
– BioGaia AB ($OTCPK:BIOGY)
Biogaia is a Swedish biotech company that markets probiotic products for infants, children, and adults. The company’s products are based on the lactic acid bacterium Lactobacillus reuteri, which is found naturally in the human gastrointestinal tract. Biogaia’s products are sold in over 60 countries worldwide.
Biogaia’s market cap is 800.05M as of 2022. The company has a Return on Equity of 10.86%. Biogaia’s products are based on the lactic acid bacterium Lactobacillus reuteri, which is found naturally in the human gastrointestinal tract. Biogaia’s products are sold in over 60 countries worldwide.
– Krka d.d. ($LTS:0HLK)
Krka d.d. is a Slovenian pharmaceutical company. It is the largest pharmaceutical company in Slovenia and one of the largest in the Balkans. The company was founded in 1959 and is headquartered in Novo mesto. Krka d.d. has a market cap of 2.77B as of 2022 and a Return on Equity of 12.85%. The company’s main products are prescription drugs, over-the-counter drugs, and medical devices.
– Phibro Animal Health Corp ($NASDAQ:PAHC)
Phibro Animal Health Corporation is a diversified animal health and specialty ingredients company with products in over 100 countries. The company’s products are sold through veterinarians, distributors, and feed stores. Phibro Animal Health Corporation’s mission is to improve the health and productivity of animals. The company’s products are used in a variety of animals, including cattle, swine, poultry, and aquaculture. Phibro Animal Health Corporation’s products are designed to improve the health and productivity of animals while providing a safe and healthy environment for them to live in.
Summary
Zoetis Inc., a global animal health company, has seen a positive sentiment in the investment market following news of its $13.5 million grant from the Bill & Melinda Gates Foundation. Zoetis Inc. has demonstrated a commitment to global animal health and investors have been impressed with its strong balance sheet, disciplined capital structure and successful track record of delivering long-term growth. The company has robust capital allocation capabilities, and its current share price reflects a healthy valuation relative to its peers. As Zoetis Inc. continues to focus on expanding its product portfolio and strategic initiatives, investors are likely to remain optimistic about the company’s prospects going forward.
